Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05378711
Other study ID # 13-718F
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 1, 2014
Est. completion date May 30, 2015

Study information

Verified date May 2022
Source Michigan State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Department of Counseling, Educational Psychology, and Special Education and the Department of Psychiatry at Michigan State University have coordinated efforts to provide a diagnostic and treatment investigation for children, ages seven to eighteen, with Selective Mutism. The purpose of this study is to examine the utility of fluoxetine for the treatment of this debilitating disorder. Fluoxetine is expected to improve social anxiety and selective mutism symptomology.


Description:

Children with selective mutism (SM) are at risk for current and continuing academic and socio-emotional difficulties. Unfortunately, this issue is complicated by the fact these children often respond poorly to psychosocial intervention. This leaves parents with the overwhelming decision to attempt a trial of medication regardless of the little available data on the evidence base of this approach. Despite the paucity of research, psychiatrists are prescribing fluoxetine for children with SM "off label", as the Food and Drug Administration (FDA) has yet to approve fluoxetine for this indication. This study blends the psychopharmacological expertise of psychiatrists with the mental health, systems, and psychological evaluation expertise of school psychologists to identify an appropriate psychopharmacological solution for children and adolescents with this debilitating disorder. To that end, this study will examine the utility of fluoxetine for the treatment of five children and adolescents, ages seven to eighteen, diagnosed with SM through the use of a non-concurrent multiple-baseline single-case design with a single-blind placebo-controlled procedure. Treatment effectiveness will be evaluated by visual analysis of the data, the Wampold and Worsham multiple-baseline design randomization test, and the Kendall's Tau + Mann-Whitney U effect size. Multiple methods of assessment including standardized measures, such as the Selective Mutism Questionnaire (SMQ), and behavior ratings, such as Direct Behavior Ratings (DBRs), will be used to gather baseline and treatment data. Multiple informants (i.e., parents, teachers, and psychiatrists) will provide information on treatment effect across settings (i.e., school and community). Information regarding adverse effects associated with fluoxetine treatment including a measure of behavioral disinhibition, parental acceptance of the fluoxetine intervention, and compliance with taking the medication will also be gathered.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date May 30, 2015
Est. primary completion date May 30, 2015
Accepts healthy volunteers No
Gender All
Age group 5 Years to 18 Years
Eligibility Inclusion Criteria: - Male or female from seven to seventeen years of age at their last birthday - Meet DSM-IV-TR criteria for selective mutism - No history of medication treatment for selective mutism - Child has an immediate biological family member who is diagnosed with an anxiety disorder or has experienced symptoms of an anxiety disorder at some point in time - Child has received 10 weeks of an evidence-based psychosocial treatment - Child has never had a negative reaction to a psychopharmacological medication - Child exhibits symptoms of social anxiety Exclusion Criteria: - Child is diagnosed with a speech condition, mental retardation, pervasive developmental disorder, or schizophrenia - Child is an English language learner or from a different culture than the culture predominately represented within his or her school - Child is taking or has taken any kind of a psychopharmacological medication (e.g., SSRI, MAO-I, stimulant, etc.) - Child has a medical illness that may be complicated through the use of a psychopharmacological treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fluoxetine
Children will receive a placebo or fluoxetine at different times dependent upon random assignment to a treatment schedule.

Locations

Country Name City State
United States Michigan State University Psychiatry Clinic East Lansing Michigan

Sponsors (1)

Lead Sponsor Collaborator
Michigan State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Treatment Integrity Form Daily for 15 weeks
Primary Selective Mutism Questionnaire (Change Over 15 Weeks) 2 times per week for 15 weeks
Secondary Multidimensional Anxiety Scale for Children - 2nd Edition (Change Over 15 Weeks) 2 times per week for 15 weeks
Secondary Direct Behavior Ratings - Parent (Change Over 15 Weeks) Parent (3 times per week for 15 weeks); Teacher (5 times per week for 15 weeks)
Secondary Clinical Global Impression (Change Over 15 Weeks) Parent and Teacher (2 times per week for 15 weeks); Psychiatrist (biweekly for 15 weeks)
Secondary Side Effects Form for Children and Adolescents - Adapted (Change Over 15 Weeks) biweekly for 15 weeks
Secondary Parent - Young Mania Rating Scale (Change Over 15 Weeks) 2 times per week for 15 weeks
Secondary Treatment Evaluation Questionnaire - Parent End of Study (after 15 weeks)
See also
  Status Clinical Trial Phase
Completed NCT05168020 - Evaluation of a Self-Monitoring Intervention to Reduce Safety Behavior in Social Anxiety N/A
Not yet recruiting NCT06020170 - Delving Into Participation Patterns in Social Anxiety Studies
Completed NCT03297619 - Self-help Books for Social Anxiety N/A
Completed NCT04509531 - Building Resilience in Cyberbullying Victims N/A
Recruiting NCT04859790 - Acceptability/Feasibility Testing of SCAR N/A
Completed NCT05576259 - oVRcome - Self Guided Virtual Reality for Social Anxiety Disorder N/A
Completed NCT05858294 - The Safety, Acceptability and Efficacy of Alena N/A
Completed NCT04450303 - Social Anxiety Telehealth Therapy Study N/A
Completed NCT03601377 - Attention Bias Modification Treatment in Social Anxiety N/A
Completed NCT03671577 - Building Closer Friendships in Social Anxiety Disorder N/A
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Recruiting NCT05554718 - Evaluation of a Smartphone Application for Self-help for Social Anxiety N/A
Completed NCT02534948 - Feasibility Study of Mindfulness and Acceptance Based Group Therapy for Social Anxiety N/A
Completed NCT03249116 - Assessing Mechanisms of Anxiety Reduction in Animal-assisted Interventions N/A
Completed NCT05159037 - Using the Musical Track From GC-MRT as a Treatment Booster in Stressful Situations N/A
Completed NCT03711513 - Facing Fears by Focussing on Behaviour, Body, or Mind? N/A
Completed NCT04845100 - Animal Assisted Activities on the Stress and Social Anxiety N/A
Active, not recruiting NCT04276363 - Families, Children and Teachers Thriving Together N/A
Completed NCT05372744 - Affect-regulatory Characteristics of Deceptive Placebos N/A
Recruiting NCT05798078 - The Relationship Between Social Anxiety and Anxious Thinking Styles N/A